Su Dan, Li Hong-Ni, Chen Qi-Cheng, Shen Dan-Ping, Huang Ze-Tao
Department of Ophthalmology, Shantou Central Hospital, Shantou, China.
Eur J Ophthalmol. 2024 Sep;34(5):1541-1547. doi: 10.1177/11206721241226469. Epub 2024 Jan 10.
This study aimed to evaluate the impact of intravitreal triamcinolone acetonide (TA) administration after peeling of idiopathic epiretinal membranes (iERM) on both anatomical and visual outcomes, utilizing the ectopic inner foveal layer (EIFL) staging scheme.
In this retrospective case-control study, we analyzed 43 eyes from 43 patients diagnosed with iERM between June 2019 and December 2021. All participants were categorized into the TA or control groups based on administering intravitreal TA injection following ERM peeling. We thoroughly reviewed the clinical data, including the preoperative and postoperative best-corrected visual acuity (BCVA), central foveal thickness (CFT), and macular cube volume (VOL), with ERM stages classified according to the EIFL staging scheme.
The study enrolled 22 eyes in the TA and 21 in the control groups. Following a mean follow-up period of 11.07 ± 2.02 months, noteworthy improvements in EIFL stages were observed in both cohorts ( < 0.01), but without significant distinctions between groups. In the TA group, 63.64% of eyes demonstrated improvements in EIFL stages, while the control group exhibited 76.19% ( = 0.37). At the final visit, both groups experienced a noteworthy reduction in the postoperative CFT and VOL ( < 0.05), coupled with significant improvement in BCVA ( < 0.01). No substantial differences appeared between the two groups concerning BCVA, CFT, and VOL (all > 0.05).
Our study suggested that concurrent intravitreal TA injection following ERM removal did not provide additional benefits regarding anatomical and visual improvement in iERM cases classified as Stages 2 and 3.
本研究旨在利用异位内黄斑层(EIFL)分期方案,评估特发性视网膜前膜(iERM)剥除术后玻璃体内注射曲安奈德(TA)对解剖结构和视力结果的影响。
在这项回顾性病例对照研究中,我们分析了2019年6月至2021年12月期间43例诊断为iERM的患者的43只眼。所有参与者根据ERM剥除术后是否进行玻璃体内TA注射分为TA组或对照组。我们全面回顾了临床数据,包括术前和术后最佳矫正视力(BCVA)、中心凹厚度(CFT)和黄斑立方体积(VOL),并根据EIFL分期方案对ERM阶段进行分类。
该研究纳入TA组22只眼,对照组21只眼。平均随访11.07±2.02个月后,两组的EIFL阶段均有显著改善(<0.01),但组间无显著差异。TA组中,63.64%的眼EIFL阶段有所改善,而对照组为76.19%(P=0.37)。在最后一次随访时,两组术后CFT和VOL均显著降低(<0.05),同时BCVA显著改善(<0.01)。两组在BCVA、CFT和VOL方面无显著差异(均P>0.05)。
我们的研究表明,在ERM切除后同时进行玻璃体内TA注射,对于2期和3期iERM病例的解剖结构和视力改善并无额外益处。